Free access to Elaprase
Tuesday, 02 September, 2008
The Hunter syndrome drug Elaprase, marketed by Genzyme Australasia, will be funded by the federal government under its life saving drugs program.
Hunter syndrome, or Mucopolysaccharidosis II, is a rare inherited enzyme disorder is caused by a deficiency in the iduronate-2-sulfatase enzyme, which is necessary for recycling certain complex carbohydrates.
Symptoms can include joint stiffness, breathing difficulties, heart problems, enlargement of the spleen an liver and skeletal deformities.
Elaprase replaces the missing enzyme needed to break down these complex carbohydrates.
Genzyme will continue providing free access to the treatment to two Hunter syndrome patients until it becomes government-funded on December 1.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
